参考文献/References:
[1]Capriglione S,Luvero D,Plotti F,et al.Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature [J].Medical Oncology,2017,34(9):164.[2]Zhu J,Wang X,Su Y,et al.Multifunctional nanolocks with GSH as the key for synergistic ferroptosis and anti-chemotherapeutic resistance[J].Biomaterials,2022,288:121704.[3]Jang DE,Song J,Park JW,et al.Protein kinase CK2 activates Nrf2 via autophagic degradation of Keap1 and activation of AMPK in human cancer cells[J].BMB Reports,2020,53(5):272-277.[4]Taguchi K,Yamamoto M.The KEAP1-NRF2 System in Cancer[J].Frontiers in Oncology,2017,7:85.[5]Tian Y,Liu Q,He X,et al.Emerging roles of Nrf2 signal in non-small cell lung cancer [J].Journal of Hematology & Oncology,2016,9:14.[6]Tossetta G,Fantone S,Montanari E,et al.Role of NRF2 in Ovarian Cancer [J].Antioxidants,2022,11(4):663.[7]Cui Q,Wang JQ,Assaraf YG,et al.Modulating ROS to overcome multidrug resistance in cancer[J].Drug Resist Updat,2018,41:1-25.[8]Saed GM,Diamond MP,Fletcher NM.Updates of the role of oxidative stress in the pathogenesis of ovarian cancer [J].Gynecologic Oncology,2017,145(3):595-602.[9]Dilruba S,Grondana A,Schiedel AC,et al.Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin [J].Cells,2020,9(2):515.[10]Yamamoto M,Kensler TW,Motohashi H.The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis [J].Physiological Reviews,2018,98(3):1169-1203.[11]Dodson M,Castro-Portuguez R,Zhang DD.NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis[J].Redox Biology,2019,23:101107.[12]Roh JL,Kim EH,Jang H,et al.Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis [J].Redox Biology,2017,11:254-262.[13]Wu M,Ma L,Xue L,et al.Resveratrol alleviates chemotherapy-induced oogonial stem cell apoptosis and ovarian aging in mice[J].Aging,2019,11(3):1030-1044.[14]Osman N,Abd El-Maqsoud NMR,El Gelany SAA.Correlation of NQO1 and Nrf2 in Female Genital Tract Cancer and Their Precancerous Lesions (Cervix, Endometrium and Ovary) [J].World Journal of Oncology,2015,6(3):364-374.[15]Liew PL,Hsu CS,Liu WM,et al.Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma [J].International Journal of Clinical and Experimental Pathology,2015,8(5):5642-5649.[16]Meng Y,Chen CW,Yung MMH,et al.DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer[J].Cancer Letters,2018,428:104-116.[17]Dharmaraja AT.Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria [J].Journal of Medicinal Chemistry,2017,60(8):3221-3240.[18]Liao W,Wang Z,Fu Z,et al.p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway [J].Free Radical Research,2019,53(7):800-814.[19]Xia MH,Yan XY,Zhou L,et al.p62 Suppressed VK3-induced Oxidative Damage Through Keap1/Nrf2 Pathway In Human Ovarian Cancer Cells[J].Journal of Cancer,2020,11(6):1299-1307.[20]Wu J,Zhang L,Li H,et al.Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression [J].Biochemical and Biophysical Research Communications,2019,518(4):698-705.[21]Bao L,Wu J,Dodson M,et al.ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells [J].Molecular Carcinogenesis,2017,56(6):1543-1553.[22]Chen J,Solomides C,Simpkins F,et al.The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy [J].Cancer Chemotherapy and Pharmacology,2017,79(2):369-380.[23]Czogalla B,Kahaly M,Mayr D,et al.Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology [J].Cancer Management and Research,2019,11:7673-7684.[24]Badmann S,Mayr D,Schmoeckel E,et al.AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin [J].Scientific Reports,2022,12(1):1862.[25]Sun X,Wang S,Gai J,et al.SIRT5 Promotes Cisplatin Resistance in Ovarian Cancer by Suppressing DNA Damage in a ROS-Dependent Manner via Regulation of the Nrf2/HO-1 Pathway [J].Frontiers in Oncology,2019,9:754.[26]Deng X,Lin N,Fu J,et al.The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer [J].Oxidative Medicine and Cellular Longevity,2020,2020:4830418.[27]Woo Y,Oh J,Kim JS.Suppression of Nrf2 Activity by Chestnut Leaf Extract Increases Chemosensitivity of Breast Cancer Stem Cells to Paclitaxel [J].Nutrients,2017,9(7):760.[28]Tomao F,Bardhi E,Di Pinto A,et al.Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status[J].Cancer Treatment Reviews,2019,80:101909.[29]Lahiguera ?魣,Hyro?觢?觢ová P,Figueras A,et al.Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors [J].EMBO Molecular Medicine,2020,12(6):e11217.[30]van der Wijst MG,Huisman C,Mposhi A,et al.Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion [J].Molecular Oncology,2015,9(7):1259-1273.[31]Yang Y,Tian Z,Guo R,et al.Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways [J].Oxidative Medicine and Cellular Longevity,2020,2020:9867595.[32]Khalil HS,Langdon SP,Goltsov A,et al.A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells[J].Oncotarget,2016,7(46):75874-75901.[33]Bian S,Zhao Y,Li F,et al.Knockdown of p62/sequestosome enhances ginsenoside Rh2-induced apoptosis in cervical cancer HeLa cells with no effect on autophagy[J].Bioscience, Biotechnology, and Biochemistry,2021,85(5):1097-1103.[34]Chen X,Yin T,Zhang B,et al.Inhibitory effects of brusatol delivered using glycosaminoglycan placental chondroitin sulfate A-modified nanoparticles on the proliferation, migration and invasion of cancer cells[J].International Journal of Molecular Medicine,2020,46(2):817-827.[35]Cucci MA,Grattarola M,Dianzani C,et al.Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism [J].Free Radical Biology & Medicine,2020,150:125-135.[36]Wu TM,Liu ST,Chen SY,et al.Mechanisms and Applications of the Anti-cancer Effect of Pharmacological Ascorbic Acid in Cervical Cancer Cells [J].Frontiers in Oncology,2020,10:1483.[37]Gao AM,Ke ZP,Wang JN,et al.Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway [J].Carcinogenesis,2013,34(8):1806-1814.
相似文献/References:
[1]杨廷双.卵巢癌患者经CT检查和MRI检查的临床效果对比[J].医学信息,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
YANG Ting-shuang.Comparison of Clinical Effects between CT and MRI in Patients with Ovarian Cancer[J].Journal of Medical Information,2018,31(16):153.[doi:10.3969/j.issn.1006-1959.2018.07.053]
[2]揭嘉慧,张 颖.卵巢癌与非编码RNA研究进展[J].医学信息,2019,32(05):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
JIE Jia-hui,ZHANG Ying.Progress in Research on Ovarian Cancer and Non-coding RNA[J].Journal of Medical Information,2019,32(16):39.[doi:10.3969/j.issn.1006-1959.2019.05.014]
[3]林斯婕,吴 璇,覃 桓,等.卵巢癌合并2型糖尿病发生的危险因素分析[J].医学信息,2019,32(05):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
LIN Si-jie,WU Xuan,QIN Huan,et al.Analysis of Risk Factors for Ovarian Cancer Complicated with Type 2 Diabetes[J].Journal of Medical Information,2019,32(16):124.[doi:10.3969/j.issn.1006-1959.2019.05.039]
[4]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Journal of Medical Information,2019,32(16):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[5]许书凡,庞 华.18F-FDGPET/CT在卵巢癌中的应用研究[J].医学信息,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
XU Shu-fan,PANG Hua.Research on the Application of 18F-FDGPET/CT in Ovarian Cancer[J].Journal of Medical Information,2019,32(16):75.[doi:10.3969/j.issn.1006-1959.2019.08.022]
[6]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Journal of Medical Information,2019,32(16):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[7]黄馨禾,董丹丹,刘 倩.PARP抑制剂在卵巢癌治疗中的研究现状[J].医学信息,2019,32(21):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
HUANG Xin-he,DONG Dan-dan,LIU Qian.Research Status of PARP Inhibitors in the Treatment of Ovarian Cancer[J].Journal of Medical Information,2019,32(16):26.[doi:10.3969/j.issn.1006-1959.2019.21.010]
[8]王 秦,张家佳,刘成桂,等.高表达IL-12卵巢癌细胞的建立[J].医学信息,2019,32(21):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
WANG Qin,ZHANG Jia-jia,LIU Cheng-gui,et al.Establishment of High Expression of IL-12 Ovarian Cancer Cells[J].Journal of Medical Information,2019,32(16):78.[doi:10.3969/j.issn.1006-1959.2019.21.024]
[9]钟达媚,张 颖.PCG与卵巢癌关系的研究[J].医学信息,2020,33(01):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
ZHONG Da-mei,ZHANG Ying.Study on the Relationship Between PCG and Ovarian Cancer[J].Journal of Medical Information,2020,33(16):28.[doi:10.3969/j.issn.1006-1959.2020.01.011]
[10]张晓黎,张 颖,陈国通,等.环状RNA在妇科恶性肿瘤中的研究进展[J].医学信息,2020,33(03):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]
ZHANG Xiao-li,ZHANG Ying,CHEN Guo-tong,et al.Study of Circular RNA in Gynecological Malignancies[J].Journal of Medical Information,2020,33(16):38.[doi:10.3969/j.issn.1006-1959.2020.03.012]